Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—Diasorin has received FDA 510(k) clearance for the Simplexa COVID-19/Flu A/B and RSV Direct kit, a sample-to-answer test for the detection of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus directly from nasopharyngeal and nasal swab specimens. The kit runs on the Liaison MDX system and provides differential detection in about 45 minutes.
December 2025—The Journal of Clinical Microbiology has published an article describing ARUP Laboratories’ validation of a deep convolutional neural network to detect parasites in concentrated wet mounts of stool.
December 2025—Smart In Media has released version 3.2 of its PathoZoom Scan and LiveView. The new version includes enhancements to workflow, image transmission, and LIS integration.
December 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research, for $225 million. The acquisition will expand Qiagen’s Sample technologies portfolio into the single-cell sequencing market with highly scalable chemistry designed to power research involving millions of billions of cells, according to a press release from Qiagen. Parse’s scalable chemistry is also expected to accelerate growth in Qiagen’s digital insights bioinformatics business.
December 2025—The FDA has approved QuidelOrtho Corp.’s Micro Typing Systems DAT card, a gel-based solution for direct antiglobulin testing, and the Ortho Vision platform, an automated blood testing system.
December 2025—The Food and Drug Administration has granted expanded clearance for use of the FecalSwab sample type across all Qiagen QIAstat-Dx gastrointestinal panels, enabling full pathogen detection, including of Shiga toxin–producing E. coli and enteropathogenic E. coli. STEC and EPEC can now be reported when testing by FecalSwab collected from stool samples with the QIAstat-Dx Gastrointestinal Panel 2, including detection of clinically relevant STEC subtypes such as stx2f. STEC can now also be reported for the QIAstat-Dx GI Panel 2 Mini B and QIAstat-Dx GI Panel 2 Mini B&V.
December 2025—Proscia is introducing virtual staining, powered by Pictor Labs, to its Concentriq software platform to help laboratories reduce the costs associated with traditional chemical methods and drive efficiency in high-throughput workflows. Virtual staining uses AI models to replicate the effects of stains on tissue images. These models can generate a whole slide virtually stained image from label-free inputs in a few minutes. The company will integrate a menu of H&E, immunohistochemical, and special stains into Concentriq.
December 2025—GSI Group Holdings has acquired GenesisBPS, a designer and manufacturer of specialized benchtop blood processing equipment and laboratory consumables. GSI Group provides a wide range of laboratory single-use products, benchtop instruments, and related accessories and has locations across the U.S., Europe, and Asia. GenesisBPS joins GSI Group brands Globe Scientific, AmScope, Euromex, and Physix, among others.
November 2025—Bio-Rad Laboratories launched Specialty Immunoassay Plus in Europe, a comprehensive immunoassay quality control product for specialty immunoassay testing procedures.
November 2025—The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for treating extensive-stage small cell lung cancer after platinum-based chemotherapy.
